Related Experiment Video
Updated: Sep 30, 2025
06:41
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
9.1K
Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication.
Paola Monari1, Giulio Gualdi2, Giorgio Bettoni3
1Department of Dermatology, ASST Spedali Civili Brescia, 25123 Brescia, Italy.
Journal of Clinical Medicine
|March 10, 2022
Summary
Post-SARS-CoV-2 telogen effluvium, a type of hair shedding, affects a significant number of COVID-19 survivors. This condition, occurring months after infection, can impact patients' quality of life.
Area of Science:
- Dermatology
- Infectious Diseases
- Pathology
Background:
- Post-SARS-CoV-2 telogen effluvium has been noted in COVID-19 patients.
- The prevalence and characteristics of this condition require further investigation.
Purpose of the Study:
- To evaluate the prevalence of post-SARS-CoV-2 telogen effluvium.
- To explore potential causal links between the infection and subsequent alopecia.
Main Methods:
- A cross-sectional study involving patients diagnosed with SARS-CoV-2 pneumonia.
- Clinical and dermatoscopic evaluations were performed by a senior dermatologist.
Main Results:
- Alopecia was observed in 31.3% of patients, predominantly females (73%).
- Hair loss typically occurred approximately 68 days after initial symptom onset.
- No significant associations were found between alopecia and COVID-19 severity, treatment, or laboratory findings.
Conclusions:
- Acute telogen effluvium is a common post-infection complication in COVID-19 patients.
- This condition can significantly affect patients' quality of life.
